2024 was a mixed year for biopharma stocks, with the iShares Biotechnology ETF and SPDR S&P Biotech ETF experiencing small decreases. Federal Reserve decisions caused a 10-day decline in biotech ETFs. StockWatch’s top five performing biotech stocks include Bright Minds Biosciences and Monopar Therapeutics while the biggest laggards were Aditxt and CNS Pharmaceuticals. Mesoblast’s American Depositary Receipts rose significantly due to FDA approval of its Ryoncil treatment.
Hackers Claim To Steal Files From App Used by Trump Adviser
Hackers have reportedly stolen messages from TeleMessage, an app used by Trump’s former national security adviser.
